Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer

John Carroll Patrick Soon-Shiong made several fortunes based on his understanding of cancer and drug development, most recently in today's multibillion-dollar IPO for NantKwest. ...

Novartis wins an early approval for a new skin cancer drug

Damian Garde Novartis won accelerated approval for a promising oncology drug, gearing up to launch a new treatment for an advanced form of the most common type of skin cancer. FierceBiotech ...

Cancer docs try to rally public behind plan to fight drug prices

Eric Palmer Cancer doctors at the famed Mayo Clinic have been up in arms about escalating prices of cancer drugs. Now they have recruited a bunch of colleagues and are trying to rile ...

Apogenix inks cancer drug development deal for China

John Carroll Germany's Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize ...

Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

Eric Palmer U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories ...

With IPO in mind, cancer player CytomX steps up with a $70M round

John Carroll FierceBiotech News

Mylan expands cancer drug recall on particle contamination worries

Tracy Staton Sterile injectable drugs are notoriously tricky to manufacture. Mylan has found that out the hard way, and it's now expanding a recall of cancer drugs that it began ...

Clovis boasts promising ovarian cancer responses for AstraZeneca rival rucaparib

John Carroll Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on ...

Genentech’s PD-L1 breakthrough star ‘atezo’ positioned to vault ahead on cancer

John Carroll Behind the headlines here at ASCO, you'll find one of the biggest players in immuno-oncology quietly positioning itself to grab a leading role in the fast-emerging ...

One of Takeda’s big cancer bets flops in a Phase III lymphoma trial

Damian Garde Alisertib, a jewel of Takeda's $ 8.8 billion acquisition of Millennium Pharmaceuticals back in 2008, failed to make the grade in a Phase III lymphoma trial, forcing ...

Mylan recalls injectable cancer meds, most produced for Pfizer

Tracy Staton Mylan is recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer, after particulate was discovered in vials. FiercePharma News

FDA reviewers raise red flags for Amgen cancer vaccine ahead of AdComm

Carly Helfand Wednesday's a big day for Amgen, whose dual-acting cancer vaccine/viral therapy is coming up for review by an FDA panel of experts. FiercePharma News
Page 4 of 23« First...23456...1020...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS